IPSC biotech catalysts & pipeline

CENTURY THERAPEUTICS INC · Data as of 2026-10-25

Upcoming catalysts

CNTY-101 — Interim data

2026

· Additional insights from ongoing CARAMEL IST expected in 2026: The company anticipates updated preliminary clinical data this year from the ongoing CARAMEL study, a Phase 1/2 investigator-sponsored trial (IST) led by Professors Georg Schett and Andreas Mackensen and sponsored by the Friedrich-Alexander University Erlangen-Nürnberg.

Source filing

CNTY-813 — IND submission

Q4 2026

CNTY-813 IND submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027

Source filing

CNTY-813 — NDA/BLA submission

4Q 2026

· Investigational New Drug (IND) submission (4Q 2026): Century expects to submit an Investigational New Drug application for CNTY-813 in the fourth quarter of 2026, subject to completion of remaining IND-enabling studies.

Source filing

CNTY-813 — Initial data

H2 2027

Initial safety and early efficacy data from the first-in-human CNTY-813 study are anticipated in the second half of 2027.

Source filing

Explore the free biotech catalyst calendar